Finance Watch: 3T Biosciences Emerges With $40m And Novel TCR Platform
Two VC Mega-Deals Revealed In Mid-August
Private Company Edition: Westlake Village BioPartners’ latest launch 3T Biosciences also licensed a second TCR platform from Stanford University. In other recent financings, Senda raised a $123m series C round, Orna revealed a $221m series B and CPRIT funded several cancer drug developers.
You may also be interested in...
Dr Gilly Regev, CEO of the anti-infectives-focused firm, SaNOtize Research & Development Corp, remains confident of the effectiveness of the firm’s nitric oxide nasal spray against evolving variants of SARS-CoV-2 and expects to progress plans for a “prevention” trial in the US.
Emerging company profile: The US biotech is wrapping up a Phase I trial for its lead pancreatic cancer program at the end of this year and hopes to expand its precision drug-device combination platform to a range of other solid tumors.
The biomanufacturing firm National Resilience has raised more than $2bn in venture capital and millions more in fees from government and industry contracts since 2020. Also, Code Biotherapeutics raised $75m in series A cash, Concert grossed $66.4m and Amarin is cutting US jobs.